Increased expression of Ifngr1, Ifngr2 and Ifnar2 in cluster 0 of the CAR-T-treated group (compared to mock-T-treated), indicates this could be a tumor adaptive mechanism to Ifn-γ and Ifn-α signaling mediated by CAR-T cell therapy (Fig. 8e). Here, IFNGR2 is linked to neoplasm.